Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
Sponsor: Jena University Hospital
Summary
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.
Official title: Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART
Key Details
Gender
MALE
Age Range
18 Years - 120 Years
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2025-09-15
Completion Date
2032-09-30
Last Updated
2025-09-08
Healthy Volunteers
No
Locations (1)
Department of Radiotherapy and Radiation Oncology, Jena University Hospital
Jena, Germany